EP2170423A2 - Implant et procédé de production associé - Google Patents

Implant et procédé de production associé

Info

Publication number
EP2170423A2
EP2170423A2 EP08759360A EP08759360A EP2170423A2 EP 2170423 A2 EP2170423 A2 EP 2170423A2 EP 08759360 A EP08759360 A EP 08759360A EP 08759360 A EP08759360 A EP 08759360A EP 2170423 A2 EP2170423 A2 EP 2170423A2
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
base body
coating
implant
lattice structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08759360A
Other languages
German (de)
English (en)
Inventor
Stephan Barcikowski
Andreas SCHÜSSLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LZH Laser Zentrum Hannover eV
Admedes Schuessler GmbH
Original Assignee
LZH Laser Zentrum Hannover eV
Admedes Schuessler GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LZH Laser Zentrum Hannover eV, Admedes Schuessler GmbH filed Critical LZH Laser Zentrum Hannover eV
Publication of EP2170423A2 publication Critical patent/EP2170423A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/082—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

  • the present invention relates to an implant according to the preamble of claim 1 and to a method for producing such an implant.
  • the implant according to the invention can be any form of device that can be inserted into the human or animal body, for example prostheses such as heart valves, joint prostheses, stents, or other implants such as inner ear implants.
  • a generic implant in the form of a stent is known from DE 199 16 086 B4.
  • Such stents generally have an elongated, hollow cylindrical shape and can be inserted into a blood vessel to keep it open.
  • stents are designed to expand after insertion into the blood vessel to relieve constriction or stenosis of the vessel.
  • Vascular stents have made significant progress in the treatment of vascular disease, but are not free of the problem and risks.
  • the stent implantation is not without risk. Especially feared are stent thromboses, ie the formation of blood clots on the stent, which almost always lead to myocardial infarction and are often fatal. Especially in drug-coated stents, a large number of late thromboses have been found in long-term studies. Studies have shown that after the placement of metallic stents in blood vessels, a cascade of reactions takes place. This begins with the coating of the stent with a thin layer of thrombus, followed by a smooth muscle cell layer, proliferation, and finally extracellular matrix accumulation, which is complete with the formation of a complete endothelial layer on the stent.
  • DE 199 16086 B4 also describes a stent with a rough surface for the purpose of better adhesion of tissue cells.
  • a base made of stainless steel an intermediate layer of gold or platinum nanoparticles with diameters of 20 to 500 nm is applied, which determines the roughness of the surface.
  • an intermediate layer On the intermediate layer is a thin outer layer of iridium oxide or titanium nitride.
  • DE 19921 088 A1 discloses a stent with a coating of paramagnetic "nanoscale particles.” The paramagnetism of the particles should be used for heating the stent or increasing the contrast in the imaging magnetic resonance.
  • EP 1 679088 A2 discloses joint prostheses with a nanostructured coating.
  • the joint prostheses consist of ceramic material.
  • WO 2004/110515 A1 describes the same stents as the abovementioned DE 103 57 742 A1
  • US 2007/0061006 A1 discloses chemical vapor deposition methods (CVD methods) for producing shape memory films, for example for stents. This produces crystalline material with particle sizes in the sub-micron range, but no nanoparticles are formed.
  • US 2006/0282172 A1 describes nanocrystalline protective coatings, for example for artificial hip joints.
  • this protective coating does not consist of individual particles but of a uniform film.
  • a disadvantage of the conventional implants has been found that they are occasionally not dimensionally stable enough in use. This is particularly important for implants such as stents, which expand after insertion into the body or otherwise change their shape. Also disadvantageous are occasionally observed corrosion or the spalling of parts of a coating.
  • the object of the present invention is to provide an implant which simultaneously promotes rapid endothelization and ensures high long-term stability.
  • the implant according to the invention has a base body and a coating of nanoparticles provided at least in sections on the surface of the base body.
  • Both the material of the main body and a material of the nanoparticles (which may have dimensions of, for example, 10 to 500 nm) have a metal grid structure.
  • the invention now provides that the lattice structure (ie, the atomic or metal lattice structure) of the material of the nanoparticles is so compatible with the lattice structure of the material of the body that the two materials by diffusion of the materials (ie by a diffusion joining process, for example by a Exchange of interstitial atoms) are connected or connected to each other. In particular, in this way not only a selective, but a surface connecting the body and the coating be possible.
  • the coating of nanoparticles gives the implant an outer surface with a roughness that favors the attachment of endothelial cells.
  • the micro- or nanoscopic spaces between the nanoparticles can be used for anchoring, for example to further promote rapid endothelialization or to prevent thrombosis formation.
  • the compatibility of the lattice structure between the material of the base body and the nanoparticles ensures that the nanoparticle coating adheres extremely firmly to the base body.
  • the reason for the extremely strong bond between body and coating is that the nanoparticles no longer adhere to the body via relatively weak adhesion forces (as in the case of conventional implants), but through the exchange of lattice sites form an extremely strong bond with the body, as in the case of Diffusion welding occurs. Even under the inhospitable environmental conditions prevailing in the human or animal body and possibly under the additional burden of targeted deformation, no parts of the coating can come off the implant. Rather, the replacement of lattice sites could continue even after the implant has been inserted under physiological conditions, thus ensuring an even stronger connection between the base body and the coating.
  • the exchange of lattice sites between the material of the base body and the material of the nanoparticles means that a material bond is formed between the base body and nanoparticle, with formation of a common phase (of nanoparticles and base body) and a common new surface , As a result of this material bond, a (substitutional) mixed crystal is formed in which no sharp phase boundary between the nanoparticle and the main body is preferably recognizable.
  • the compatibility ie the favorable ratio between the atomic lattice spacing of the base body material and the atomic lattice spacing of the coating
  • a very high strength between the joining partners main body and coating can be achieved, since a diffusion of atoms into a substitution mixed crystal or the diffusion of individual material atoms into the interstitial sites of the respective other material is facilitated.
  • the possibility for such a diffusion is just the prerequisite for a For example, for diffusion bonding or, more precisely, diffusion joining (since the method can do without the temperatures and pressures required for welding, the term "joining" is more appropriate.)
  • the method according to the invention also enables a particularly high degree of freedom in terms of geometry with simultaneously comparatively inexpensive process conditions.
  • coating with nanoparticles may also reduce the friction between the implant (eg, a stent) and a delivery system through which the implant is inserted into the body. This would be advantageous in particular for long "peripheral" stents, i.e. for stents for use in the peripheral region of the blood circulation, which often can only be released with considerable difficulty.
  • the material of the base body and the material of the nanoparticles substantially (i.e., with a maximum deviation of about 5%) have the same electrochemical potential, it is ensured that corrosion between the coating and the base body is effectively suppressed. In this way, the long-term stability of the implant is further improved. On passivating intermediate layers can be dispensed with.
  • the base body and the nanoparticles of the coating are formed from the same material. This ensures a complete adaptation of the lattice structures and thus a particularly strong, stable connection of the coating.
  • the implant is to be deformable, for example an expandable stent
  • shape memory materials such as a nickel-titanium alloy are particularly advantageous for this purpose.
  • the material of the main body is such a nickel-titanium alloy
  • the nanoparticles may comprise one or more of the following materials with which a good adaptation of the metal lattice structures is achieved: a) titanium (Ti), b) nickel-titanium ( NiTi) c) Ni (x) Ti (y), where x and y are complementary (nearly) 1, d) NiTiX, ie nickel-titanium with an incorporation or an alloying partner "X", eg as NiTiAg with an antibacterially active silver intercalation, e) TiOx, f) TiOx (OH) y, where x and y are too (nearly) 1, or g) Ni (x) Ti (y) O (z) H (n), where x, y, z and n are
  • an adaptation of the lattice structures is advantageous. It ensures that the pseudo-elasticity of the implant or the shape memory actuator effect of the basic body does not change (at most extremely slightly) by the application of the coating. Since the base body and the coating deform in the same way and are also very firmly connected to each other, a flaking of the coating can be effectively prevented.
  • the body material could also be a Co-Cr alloy (e.g., one of the stent alloys L-605 or MP-35N) or a stainless steel (e.g., 316-L).
  • a Co-Cr alloy e.g., one of the stent alloys L-605 or MP-35N
  • a stainless steel e.g., 316-L
  • diffusion-compatible materials for the nanoparticle coating in such cases, e.g. Chromium alloys or biocompatible steels or iron alloys are suitable.
  • the main body has an outer surface and an inner surface and the coating is provided only on one of the two surfaces, in order to favor in this way the attachment of new endothelial cells targeted to this coated surface.
  • the coating could also be provided on both the outer surface and the inner surface of the base body, e.g. An attachment of tissue cells on both surfaces is considered advantageous.
  • the coating does not have to be present on the entire surface of the base body in order to enable rapid endothelization. Rather, it is sufficient if the nanoparticle coating is provided on 30% to 70% of the surface of the base body, preferably to about 50%. In this coated area, tissue cells accumulate, which are subsequently A very short endothelization can also be achieved with a merely incomplete, but therefore cost-effective, coating of the main body.
  • the nanoparticle coating does not have to form the outside of the implant, but it could still be provided with a coating of one or more layers.
  • the invention also relates to a method for producing an implant, wherein a nanoparticle coating is applied to a base body and the metal lattice structures of the material of the base body and of the material of the nanoparticles are compatible with one another. In this way, an extremely strong, permanent connection between the body and the coating is achieved.
  • the nanoparticles on the base are available as variants, for example, a coating in a dip with a colloidal nanoparticle suspension, a spray coating and / or an electrophoretic deposition of the nanoparticles on the body available.
  • Particularly advantageous here is the high freedom of the basic body geometry, which depends only on the degree of wetting with a liquid and is free from shadowing effects.
  • peripheral stents with particularly small diameters or stents with a high proportion of material (few cutouts) can be coated without any adverse effects.
  • a process at room temperature can be comparatively inexpensive and - Warm-up times - be done very quickly.
  • the application and the firm adhesion of the nanoparticles takes place in a temperature range to which the implant is exposed even after insertion into the body.
  • the application of the nanoparticles according to the invention takes place under atmospheric pressure, which has both cost advantages and process advantages over vacuum coating processes.
  • the nanoparticles can combine with the material of the main body by a diffusion process, in particular a diffusion joining.
  • the resulting bond between the nanoparticle coating and the base body is extremely strong due to the exchange of lattice sites.
  • parts of the surface of the main body are shielded before and / or during the application of the nanoparticles in order not to be coated with nanoparticles.
  • Such uncoated areas could e.g. be used for better handling of the implant or for marking certain areas of the implant. It is also possible to shield only one of the two surfaces in the case of a base body with an outer and an inner surface, so that the coating only reaches the other of the two surfaces.
  • a cover could be used which is removed again after application of the nanoparticles, for example a layer of a detachable polymer or an elastic tube.
  • the nanoparticles could be obtained by various methods. It has proven to be particularly advantageous to obtain the nanoparticles by ablation or "knocking out” from a substrate by means of a pulsed laser, in particular a short-pulse laser or ultrashort pulse laser, because the size of the nanoparticles can be precisely adjusted via the choice of the laser parameters and the focusing
  • the removal or "knocking out” of the nanoparticles from a substrate by means of a pulsed laser is due to the extremely short exposure times of the laser (with pulse durations in the nano-, pico- or femtosecond range) without a significant input of heat into the substrate or the particles.
  • the atomic lattice structure of the substrate material is retained - and a pre-set compatibility of the atomic lattice structures between the substrate material and the material of the base body is transferred in an ideal way on the nanoparticles.
  • the nanoparticles produced in this way are therefore particularly well suited for the desired diffusion bonding process.
  • the substrate is made of the same material as the base body or by Laserabtrage ⁇ made of the same material.
  • the basic body itself or a structurally identical basic body could be used as the substrate from which the nanoparticles are obtained.
  • the nanoparticles also consist of the same material as the main body, so that they also have exactly the same metal lattice structure as the material of the main body, so that the lattice structures are optimally diffusion-compatible.
  • the coating could still be provided with at least one thin, single-layer or multi-layer coating.
  • a great advantage of the method according to the invention is that it allows the simultaneous, parallel coating of a large number of basic bodies with nanoparticles. By e.g. several 10, several 100 or even several 1000 implants are coated at the same time, the unit costs can be reduced enormously.
  • the parallel production has the advantage that the implants can be coated under the same conditions and therefore the characteristic of the coating should be the same for all implants. For quality assurance, it is therefore sufficient to check and document the manufacturing process for individual products produced in parallel.
  • FIG. 1 shows an embodiment of an implant according to the invention in the form of a stent
  • Fig. 2 is a vertical section through the stent shown in Fig. 1 at the designated in Fig. 1 with H-II location.
  • 1 shows a plan view of an exemplary embodiment of an implant 1 according to the invention, which is designed here as a stent for insertion into a blood vessel.
  • the stent 1 has a main body 2, which has a form of a hollow cylinder, reticulate shape.
  • the net-like structure of the base body 2 is formed in this case by two mutually obliquely extending flocks of network strands 3, wherein the strands of a crowd 3 each run parallel to each other and are connected at node 4 with the strands 3 of the other crowd.
  • the entire base body 2 of the implant may be formed in one piece.
  • the base body 2 is formed from a metallic shape memory material, which consequently has an internal metal grid structure.
  • the material may be a nickel-titanium alloy (NiTi or "Nitinol”) .
  • NiTi nickel-titanium alloy
  • NiOl nickel-titanium alloy
  • Fig. 2 shows a vertical section through the stent 1 at the designated in Fig. 1 with U-Il point. The cut follows the course of the network strands 3 of the main body. 2
  • the base body 2 Due to its hollow cylindrical shape of the base body 2 has an outer surface 5 and an inner surface 6. While in the illustrated embodiment, the inner O- ber Structure 6 is free of coating, on the outer surface 5, a coating 7 is applied. However, as a rule, (possibly even exclusively) the inner surface 6, i. the blood stream facing surface of the stent 1, provided with a coating 7. For the embodiment variant as a stent 1, an inner coating may even be particularly advantageous.
  • the coating 7 can also be provided at the ends or side edges of the stent 1 in order to accelerate the endothelization there as well.
  • the coating 7 consists of nanoparticles 8, i. from particles with particle sizes of less than one micrometer. In particular, the nanoparticles 8 may have the same or different diameters in the range of about 10 nm to 500 nm.
  • the material comprising at least a part of the nanoparticles 8 has a metal lattice structure that corresponds to the metal lattice structure of the material of the basic structure.
  • Body 2 is largely compatible, if not the same.
  • the nanoparticles could be, for example, titanium (Ti), nickel-titanium (NiTi), Ni (x) Ti (y), TiOx, TiOx (OH) y, Ni (x) Ti (y) O (Z) comprise H (n) or combinations of these materials whose metal lattice structure closely matches that of NiTi.
  • the lattice structures should preferably be compatible in such a way that an exchange of lattice sites is possible when attaching the nanoparticles to the base body.
  • the coating 7 has a thickness of about 20nm up to 500nm. However, it could also be higher, for example up to 1.0 or 1.5 ⁇ m.
  • the two dashed arrows indicate that the coating can extend around the entire base body 2, even if only a small section of the coating 7 is shown.
  • uncoated sections or "coating gaps" 9 are also provided between coated sections of the main body 2. The “coating gaps” 9 are formed at areas which are covered during the application of the nanoparticles 8.
  • the rough surface of the implant 7 provides ideal conditions for attaching endothelial cells while not supporting the unwanted attachment of smooth muscle cells.
  • the outside of the coating 7 may optionally be provided with a single- or multi-layered film-like coating which does not substantially alter the surface topography of the implant.
  • the coating could contain drugs or other substances that favor the attachment of certain cell types.
  • the implant 1 is produced by first forming the main body 2 and separately producing the nanoparticles 8 for this purpose.
  • the nanoparticles 8 are formed by removal of a substrate or base material by means of a short pulse or ultrashort pulse laser.
  • the size of the nanoparticles 8 removed from the substrate can be adjusted via the parameters of the laser, above all via the pulse energy and the pulse length.
  • This type of nanoparticle generation is described in the articles "Continuous Production and Online Characterization of Nanoparticles from Ultrafast Laser Ablation and Laser Cracking" by S. Barcikowski et al., Proceedings of the 23rd International Conference on Applications of Lasers and Electrodes. Optics ICALEO 2005, 31.Oct.-03.Nov, Miami, CA, USA, pp.
  • laser ablation from the substrate can be carried out in a liquid environment because the nanoparticles are thus dispersed and colloidally stabilized immediately after ablation, thus retaining as "individual" nanoparticles without aggregating into larger agglomerates It would also be possible to anneal the abraded material to obtain the stoichiometry if one of the alloying partners is otherwise found in the nanoparticles to a negligible extent.
  • the nanoparticles 8 are then applied to the base body 2.
  • the application of the nanoparticles 8 can be carried out after a (electro) polishing of the main body 2.
  • the application takes place at room temperature, for example by electrophoretic deposition.
  • the deposited nanoparticles exchange 8 lattice sites with the material of the base body 2.
  • This compound is so strong that even with an expansion of the stent 1 (stent dilation) flake off parts of the coating 7 in any case. Overall, this results in an implant 1 with a particularly good long-term stability.
  • the exchange of atoms in the crystal lattice structure takes place after application of the nanoparticles 8 on the base body 2 at room temperature, in order to achieve a sufficiently strong attachment of the nanoparticles 8 to the base body 2.
  • An even stronger attachment of the nanoparticles 8 can be achieved by the temperature of the implant 1 is raised after the application of the nanoparticles 8 on the base body 2 to a diffusion diffusion temperature which is higher than room temperature, and thus the substantial proportion of Diffusionsglagereaes he follows. Since with the higher diffusion temperature more atoms from the lattice structure of the nanoparticles exchange their place with atoms from the lattice structure of the base body 2, the nanoparticles 8 are then much more firmly connected to the base body 2.
  • the post-processing after the application of the nanoparticles 8 is preferably carried out at a (diffusion) temperature and a pressure which lies below the melting point or the sublimation point of the material of the nanoparticles 8 and the base body 2 in the pressure-temperature phase diagram.
  • the temperature is in the range of 60 to 80% of the melting or tempering temperature of the material, or slightly below, so as to minimize grain growth.
  • the diffusion bonding process may preferably be performed at a temperature below 300 ° C, preferably below 150 ° C.
  • other diffusion fusing temperatures may be advantageous.
  • the invention could be modified in many ways. It should be emphasized that the invention is not limited to stents, but that other implants such as heart valves, heart valve support structures, blood filters, occlusive devices, vascular connectors, stent-grafts, etc., could also be coated with a corresponding coating of nanoparticles.
  • the invention when applied to stents, it in no way has to have the form shown by way of example only in FIG. Rather, the shape of the stent could be significantly more complicated. Nor is it necessary that the main body of the stent consists of a shape memory material. Rather, it would also be possible stents made of steel or similar, which are expanded via a balloon introduced into it.
  • nanoparticle coating or in the pores of the coating could drugs, genes, growth factors o.a. be deposited or stored, which have a positive effect on the environment of the implant.
  • room temperature offers advantages in terms of process technology, it could also be carried out at other temperatures (and pressures), for example at 4-100 ° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne un implant (1) comprenant un corps de base (2) présentant une surface (5, 6) et au moins un revêtement (7) composé de nanoparticules (8), placé sur la surface (5, 6) du corps de base (2). Ledit corps de base (2) est fabriqué dans un matériau comportant une structure grillagée métallique et les nanoparticules (8) du revêtement (7) présentent un matériau qui présente également une structure grillagée métallique. L'implant est caractérisé en ce que la structure grillagée du matériau des nanoparticules (8) est compatible avec la structure grillagée du matériau du corps de base (2), de sorte que les deux matériaux peuvent être reliés entre eux par un processus de diffusion, en particulier par un processus d'assemblage par diffusion. L'invention concerne également un procédé de production dudit implant, qui permet, notamment, le revêtement simultané d'une pluralité d'implants (1) dans des conditions de traitements 'douces'.
EP08759360A 2007-06-27 2008-06-27 Implant et procédé de production associé Withdrawn EP2170423A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007029672A DE102007029672A1 (de) 2007-06-27 2007-06-27 Implantat und Verfahren zu dessen Herstellung
PCT/EP2008/005288 WO2009000550A2 (fr) 2007-06-27 2008-06-27 Implant et procédé de production associé

Publications (1)

Publication Number Publication Date
EP2170423A2 true EP2170423A2 (fr) 2010-04-07

Family

ID=40075912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08759360A Withdrawn EP2170423A2 (fr) 2007-06-27 2008-06-27 Implant et procédé de production associé

Country Status (4)

Country Link
US (1) US20100178311A1 (fr)
EP (1) EP2170423A2 (fr)
DE (1) DE102007029672A1 (fr)
WO (1) WO2009000550A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008064667B4 (de) * 2008-07-15 2011-06-09 Lzh Laserzentrum Hannover E.V. Verfahren zur Herstellung eines Detektionskonjugats
WO2013190793A1 (fr) * 2012-06-18 2013-12-27 パナソニック株式会社 Dispositif de détection infrarouge
DE102019104827B4 (de) * 2019-02-26 2020-12-17 Acandis Gmbh Intravaskuläres Funktionselement, System mit einem Funktionselement und Verfahren

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5477864A (en) 1989-12-21 1995-12-26 Smith & Nephew Richards, Inc. Cardiovascular guidewire of enhanced biocompatibility
US5725573A (en) 1994-03-29 1998-03-10 Southwest Research Institute Medical implants made of metal alloys bearing cohesive diamond like carbon coatings
AU749980B2 (en) 1997-11-07 2002-07-04 Advanced Bio Prosthetic Surfaces, Ltd. Metallic Intravascular Stent and Method of Manufacturing a Metallic Intravascular Stent
DE19916086B4 (de) 1998-04-11 2004-11-11 Inflow Dynamics Inc. Implantierbare Prothese, insbesondere Gefäßprothese (Stent)
GB9908427D0 (en) * 1999-04-13 1999-06-09 Deltex Guernsey Ltd Improvements in or relating to ultrasound devices
DE19921088C2 (de) 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent zur Offenhaltung gangartiger Strukturen
US6379383B1 (en) 1999-11-19 2002-04-30 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal device exhibiting improved endothelialization and method of manufacture thereof
DE10026485A1 (de) * 2000-05-29 2001-12-13 Udo Heinrich Grabowy System mit einem Trägersubstrat mit einer Ti/P- bzw. AI/P-Beschichtung
US6805898B1 (en) * 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US7048767B2 (en) * 2002-06-11 2006-05-23 Spire Corporation Nano-crystalline, homo-metallic, protective coatings
US20060100716A1 (en) * 2002-06-27 2006-05-11 Reto Lerf Open-pored metal coating for joint replacement implants and method for production thereof
US7824462B2 (en) * 2003-03-27 2010-11-02 Purdue Research Foundation Metallic nanoparticles as orthopedic biomaterial
US20060287710A1 (en) * 2003-06-13 2006-12-21 Minemoscience Gmbh Biodegradable stents
DE10357742A1 (de) * 2003-06-13 2005-03-10 Mnemoscience Gmbh Temporäre Stents zur nicht-vaskulären Verwendung
US20050113936A1 (en) * 2003-10-30 2005-05-26 Brustad John R. Surface treatments and modifications using nanostructure materials
US20050119723A1 (en) 2003-11-28 2005-06-02 Medlogics Device Corporation Medical device with porous surface containing bioerodable bioactive composites and related methods
DE10361941A1 (de) * 2003-12-24 2005-07-28 Restate Patent Ag Magnesiumhaltige Beschichtung
US20060184251A1 (en) * 2005-01-07 2006-08-17 Zongtao Zhang Coated medical devices and methods of making and using
WO2006090005A1 (fr) * 2005-02-23 2006-08-31 Pintavision Oy Procede de depot au laser a impulsion
US20080249607A1 (en) * 2005-09-20 2008-10-09 Thomas Jay Webster Biocompatable Nanophase Materials
US8187660B2 (en) * 2006-01-05 2012-05-29 Howmedica Osteonics Corp. Method for fabricating a medical implant component and such component
ITFI20060034A1 (it) * 2006-02-03 2007-08-04 Colorobbia Italiana Spa Processo per la funzionalizzazione di superfici metalliche in titanio con particelle di titanio nanometriche e prodotti cosi' funzionalizzati
DE102006007231B4 (de) * 2006-02-15 2009-04-09 Acandis Gmbh & Co. Kg Verfahren zur Umhüllung eines Stents
US20070259427A1 (en) * 2006-03-27 2007-11-08 Storey Daniel M Modified surfaces for attachment of biological materials
US7955383B2 (en) * 2006-04-25 2011-06-07 Medtronics Vascular, Inc. Laminated implantable medical device having a metallic coating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009000550A3 *

Also Published As

Publication number Publication date
US20100178311A1 (en) 2010-07-15
WO2009000550A2 (fr) 2008-12-31
WO2009000550A3 (fr) 2009-12-17
DE102007029672A1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
DE69829015T2 (de) Wirkstoffhaltige poröse Metallprothesen
DE10145714B4 (de) Stent
DE10107795B4 (de) Gefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze
DE60114576T2 (de) Intraluminare, durchlöcherte, radial ausweitbare prothese zur zufuhr von medikamenten
DE60310686T2 (de) Metallverstärkter bio-abbaubarer intraluminaler stent
DE60032102T2 (de) Beschichtung für einen stent
DE29624503U1 (de) Arzneimittel-freisetzender beschichteter Stent
EP1984033B1 (fr) Procédé d'enveloppement d'un stent
EP2224970B1 (fr) Implant et procédé de revêtement d'un implant
EP1419793A1 (fr) Endoprothese avec une structure porteuse en alliage de magnesium
EP2630978B1 (fr) Implant et son procédé de fabrication
EP2055328B1 (fr) Stent doté d'un corps de base constitué d'une matière bioinerte métallique
DE102008054845A1 (de) Vorrichtung und Verfahre zur Herstellung derselben
WO2009000550A2 (fr) Implant et procédé de production associé
EP1610723A1 (fr) Stent
EP2806981B1 (fr) Procédé pour revêtir une endoprothèse
WO2005075005A1 (fr) Implant permettant de liberer une substance active dans un recipient traverse par un fluide corporel
EP2678047A1 (fr) Implant en alliage de magnésium biocorrodable
EP2385846A2 (fr) Implant médical et procédé de production d'un tel implant
EP2593151A1 (fr) Implant médical et procédé de fabrication d'un tel implant
EP3643337B1 (fr) Stent pour l'implantation dans une cavité d'un corps humain ou animal ainsi que procédé de fabrication d'une structure de couches opaque aux rayons x sur un stent
DE102012200910A1 (de) Vorrichtung zur Beschichtung eines Stents und dazugehöriges Beschichtungsverfah-ren sowie nach dem Verfahren hergestellter Stent
DE102012213781A1 (de) Medizinische Hybridimplantate
WO2015144760A1 (fr) Procédé d'application de particules chargées sur un implant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20101117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130103